Search for a trial

Treatment study for children and adolescents with Acute Promyelocytic Leukemia

This study has been transitioned to CTIS with ID 2024-518669-83-00 check the CTIS register for the current data. Primary objective:To assess, in an international pediatric study, the efficacy, in terms of event-free survival, of a combination of ATO…

CHIP-AML22 Master protocol: An open label complex clinical trial in newly diagnosed pediatric de novo AML patients - a study by the NOPHO-DBSHIP consortium

This study has been transitioned to CTIS with ID 2023-504999-25-00 check the CTIS register for the current data. To investigate wether the treatment of children and adolescents with AML can be improvedby means of:1) improved risk-group adapted…

Assessing Overall Survival, Quality of Life, Frailty, Comorbidity Indexes, Healthcare Usage, and Pharmacoeconomics in Elderly Patients with Acute Myeloid Leukemia

Primary Objective:- To assess and describe Quality of Life throughout a patients treatment trajectorySecondary Objective(s):- To assess and describe how frail unselected real world AML patients are at diagnosis using geriatric screening tools (G8, 6…

CHIP-AML22/Quizartinib: A phase II, single arm, open label, study on the safety, efficacy, pharmacokinetics and pharmacodynamics of quizartinib in combination with chemotherapy and as single-agent after high dose therapy in newly diagnosed pediatric FLT3-ITD positive and NPM1 wild type AML patients.
(A linked-trial of the CHIP-AML22/Master protocol by the NOPHO-DB-SHIP consortium)

This study has been transitioned to CTIS with ID 2023-505000-27-01 check the CTIS register for the current data. To investigate the safety and efficacy of quizartinib in children and adolescents with newly diagnosed FLT3-ITD positive AML with normal…

International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children. Sub-Protocol D: Trametinib + Dexamethasone
+ Cyclophosphamide and Cytarabine in pediatric patients with relapsed or refractory hematological malignancies

This study has been transitioned to CTIS with ID 2022-501869-41-00 check the CTIS register for the current data. PrimaryPhase I: To assess the safety and tolerability of the investigational agents and define the MTD/RP2D(s)Phase II: To evaluate the…

A Randomized, Multi-Center Phase III Trial comparing two conditioning regimens (CloFluBu and BuCyMel) in children with Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation.

This study has been transitioned to CTIS with ID 2023-505512-37-00 check the CTIS register for the current data. The primary objective of the randomized part of the protocol is to investigate if a conditioning regimen containing one alkylator (Bu)…

Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study)

This study has been transitioned to CTIS with ID 2023-503640-14-00 check the CTIS register for the current data. Primary:• To compare event-free survival (EFS) of subjects receiving blinatumomab alternating with low-intensity chemotherapy to EFS of…

Quality of life, Survival, COmorbidities, and Pharmacoeconomics in Elderly patients with Acute Myeloid Leukemia

We aim to measure quality of life and overall survival in patients with AML classified as ineligible for intensive chemotherapy and get treated with HMA combination regimens in the Medical Centre Leeuwarden. We also aim to determine the predictive…